Physician profile
Charlene Mitchell
NPI 1841663929
$807.23
in general payments reported to CMS, 2019-2025
16 companies · $534 in 2025
The $534 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $274 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $667.23 |
| Education | $140.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $231.69 | 2024-2025 | Cresemba, Xospata |
| Incyte Corporation | $143.33 | 2025 | Jakafi, Jakafi |
| E.R. Squibb & Sons, L.L.C. | $121.88 | 2025 | Breyanzi |
| Janssen Biotech, INC. | $52.31 | 2024-2025 | Darzalex, Carvykti |
| Taiho Oncology, INC. | $38.37 | 2024 | |
| Sanofi-Aventis U.S. LLC | $32.40 | 2025 | |
| Celgene Corporation | $25.92 | 2025 | Breyanzi |
| Amgen INC. | $22.24 | 2025 | Blincyto |
| Legend Biotech USA INC. | $21.57 | 2024 | |
| Merck Sharp & Dohme LLC | $20.04 | 2025 | Prevymis |
| Astrazeneca Pharmaceuticals LP | $19.35 | 2025 | |
| Abbvie INC. | $18.83 | 2025 | |
| Genentech USA, INC. | $16.02 | 2025 | Venclexta |
| Daiichi Sankyo INC. | $15.50 | 2024 | Vanflyta |
| Cumberland Pharmaceuticals, INC. | $14.62 | 2024 | Sancuso |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $13.16 | 2024 | Yescarta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlene Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.